BRAF gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png BRAF gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-plixorafenib-fore8394-for-patients-with-cancer-having-braf-alterations/ Wed, 29 Apr 2026 15:00:20 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-plixorafenib-fore8394-for-patients-with-cancer-having-braf-alterations/ This clinical trial is focused on studying certain types of cancer that have changes in a gene called BRAF. These changes are known as BRAF alterations. The trial is testing a new treatment called Plixorafenib, also known by its code name FORE8394. This treatment is designed to target and inhibit specific changes in the BRAF gene, which are found in some cancers. The purpose of the study is to evaluate how effective and safe Plixorafenib is for patients with these specific genetic changes in their cancer.

The study involves two main groups of participants. The first group includes individuals with advanced or spreading solid tumors or certain brain tumors that have a specific type of BRAF change called a BRAF fusion. The second group includes individuals with a type of brain tumor known as high-grade glioma that has a different BRAF change called the BRAF V600E mutation. Participants in the study will receive the treatment in the form of tablets taken by mouth. The study will last for a period of up to 120 days, during which the effects of the treatment will be closely monitored.

Throughout the study, participants will be assessed to determine how well the treatment is working and to monitor any side effects. The study aims to gather information on the treatment’s impact on the cancer and its safety profile. This information will help researchers understand the potential benefits and risks of using Plixorafenib for treating cancers with BRAF alterations.

]]> Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity https://clinicaltrials.eu/trial/study-on-treating-advanced-cancers-with-braf-mutations-using-sorafenib-and-trametinib-for-patients-with-impaired-kinase-activity/ Wed, 29 Apr 2026 14:58:37 +0000 https://clinicaltrials.eu/trial/study-on-treating-advanced-cancers-with-braf-mutations-using-sorafenib-and-trametinib-for-patients-with-impaired-kinase-activity/ This clinical trial is focused on studying advanced-stage cancers that have a specific change in their genes known as BRAF mutations. These mutations affect how certain proteins work in the body. The study is testing a combination of two medications: Sorafenib and Trametinib. Sorafenib is also known by the brand name Nexavar, and Trametinib is known as Mekinist or by its code name GSK1120212B. Both medications are taken as film-coated tablets by mouth.

The purpose of the study is to find the best dose of these medications when used together. Participants will receive both Sorafenib and Trametinib to see how their cancer responds to the treatment. The study will monitor how well the treatment works and any side effects that may occur. The trial will continue until the researchers determine the most effective and safe dose for future studies.

Participants in the study will have regular check-ups and tests, such as MRI or CT scans, to measure the size of their cancer and assess their overall health. The study aims to provide valuable information that could lead to better treatment options for people with cancers that have BRAF mutations.

]]>